Definium Therapeutics
DFTX
101 hedge funds and large institutions have $20.5M invested in Definium Therapeutics in 2022 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 34 reducing their positions, and 72 closing their positions.
240% more call options, than puts
Call options by funds: $20.9M | Put options by funds: $6.14M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
37% more capital invested
Capital invested by funds: $14.9M → $20.5M (+$5.59M)
19.01% more ownership
Funds ownership: 0.36% → 19.37% (+19%)
0% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 34
35% less funds holding
Funds holding: 155 → 101 (-54)
75% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 72
Top Buyers
Top Sellers
| 1 |
Millennium Management
New York
|
-$1.76M |
| 2 |
E
Ergoteles
New York
|
-$696K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$405K |
| 4 |
LPL Financial
San Diego,
California
|
-$324K |
| 5 |
PCM
Penserra Capital Management
Orinda,
California
|
-$282K |
DFTX Hedge Fund Activity: Q3 2022 in Review
101 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q3 2022, worth a combined $20.5M — up 37% from $14.9M a quarter earlier.
Sellers outnumbered buyers: 72 funds closed out of DFTX and 18 opened new positions — a net loss of 54 holders — while 34 trimmed existing stakes and 34 added.
The largest buyer was Data Collective IV, adding an estimated $13.5M. The largest seller was Millennium Management, cutting an estimated $1.76M.
- 101 institutional investors held Definium Therapeutics (DFTX) as of Q3 2022, down from 155 in Q2 2022.
- Funds reported $20.5M of Definium Therapeutics stock for Q3 2022, up 37% quarter-over-quarter.
- 18 funds opened new Definium Therapeutics positions in Q3 2022 and 72 closed out, a net change of -54 holders.
- The largest Definium Therapeutics buyer in Q3 2022 was Data Collective IV, an estimated $13.5M added.
- The largest Definium Therapeutics seller in Q3 2022 was Millennium Management, an estimated $1.76M sold.
Based on aggregated 13F filings for Q3 2022.